At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
single 1500 mg dose of Ferriproxdrug
Likely dose
single 1500 mg dose of Ferriproxfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Pharmacokinetic Profile of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
In Brief
A Phase 1 clinical trial evaluating single 1500 mg dose of Ferriprox for Sickle Cell Disease. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the pharmacokinetics of deferiprone and its 3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in patients with sickle cell disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartMay 2013
Primary CompletionApr 2014
TodayJul 2026
First PostedApr 19, 2013
Enrollment StartMay 1, 2013
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.2 years ago
Interventions
single 1500 mg dose of Ferriproxdrug
A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions